Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176904 · ClinicalTrials.gov registry record · Phase 2
Stem Cell Transplant for Inborn Errors of Metabolism
A Phase 2 study of Batten Disease and Adrenoleukodystrophy, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 1
- Study location
NCT00176904 is a Phase 2 study of Batten Disease and Adrenoleukodystrophy that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 135 participants, below the 2,817-participant average among 11 other Batten Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00176904, a Phase 2 study of Batten Disease and Adrenoleukodystrophy, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and engraftment of donor hematopoietic cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming) cell transplant for an inherited metabolic storage disease.
Conditions Studied
Interventions
- PROCEDURE Stem Cell Transplant
- DRUG Busulfan, Cyclophosphamide, Antithymocyte Globulin
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 1995-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176904
The ClinicalTrials.gov registry entry for NCT00176904 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,817-participant average among 11 other Batten Disease trials with a reported enrollment target (95% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Batten Disease appearing as the primary indexed condition, and to 2 interventions - of which Stem Cell Transplant is the first listed.
NCT00176904 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00176904 about?
NCT00176904 is a clinical study titled "Stem Cell Transplant for Inborn Errors of Metabolism". The purpose of this study is to determine the safety and engraftment of donor hematopoietic cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming) cell transplant for an inherited metabolic storage disease.
What is the current status of trial NCT00176904?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 1995-01. Estimated completion is 2010-06.
What conditions does trial NCT00176904 study?
This clinical trial studies the following conditions: Batten Disease, Adrenoleukodystrophy, GM1 Gangliosidosis, Tay-Sachs Disease, Wolman Disease.
What interventions are being tested in trial NCT00176904?
The interventions under investigation include: Stem Cell Transplant (PROCEDURE), Busulfan, Cyclophosphamide, Antithymocyte Globulin (DRUG).
Who is sponsoring clinical trial NCT00176904?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00176904 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Batten Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease
COMPLETED · Phase 2
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
-
Clinical and Neuropsychological Investigations in Batten Disease
RECRUITING
-
NYSCF Scientific Discovery Biobank
RECRUITING
-
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
RECRUITING · Phase 1
-
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.